
Neovasc NVCN
Annual report 2021
added 12-23-2023
Neovasc Gross Profit 2011-2026 | NVCN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Neovasc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.99 M | 1.51 M | 1.63 M | 1.38 M | 1.91 M | 2.42 M | 2.99 M | 4.95 M | 4.38 M | 3.2 M | 2.02 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.95 M | 1.38 M | 2.58 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
11.1 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
1.65 B | $ 38.94 | -0.84 % | $ 5.8 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
247 M | $ 8.08 | 3.32 % | $ 580 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.1 | 2.76 % | $ 153 M | ||
|
Electromed
ELMD
|
50 M | $ 24.37 | 1.61 % | $ 206 M | ||
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 9.68 | 2.93 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.54 | 0.22 % | $ 122 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
750 M | $ 43.25 | -0.37 % | $ 1.34 B | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
167 M | $ 29.55 | -0.94 % | $ 1.36 B | ||
|
Apyx Medical Corporation
APYX
|
33.8 M | $ 3.29 | 3.79 % | $ 114 M | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
InMode Ltd.
INMD
|
291 M | $ 13.55 | -0.37 % | $ 876 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
IRadimed Corporation
IRMD
|
56.3 M | $ 106.02 | 1.66 % | $ 1.34 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
147 M | $ 0.52 | -1.69 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
LivaNova PLC
LIVN
|
940 M | $ 66.16 | -3.31 % | $ 3.61 B | ||
|
Medigus Ltd.
MDGS
|
6.68 M | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
62 M | $ 1.47 | -4.25 % | $ 57.5 M | ||
|
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.79 | -1.2 % | $ 43 M | ||
|
Medtronic PLC
MDT
|
19.6 B | $ 95.93 | -0.83 % | $ 123 B | ||
|
Align Technology
ALGN
|
2.8 B | $ 181.24 | -0.77 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
339 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
48.8 M | $ 3.97 | 7.3 % | $ 840 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
18.7 B | $ 113.32 | -0.26 % | $ 197 B | ||
|
NuVasive
NUVA
|
865 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
270 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
13.9 B | $ 72.88 | -1.31 % | $ 108 B |